PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3986.96%
Revenue growth of 3986.96% while AXSM is flat. Bruce Berkowitz would check if a small edge can widen further.
804.39%
Positive gross profit growth while AXSM is negative. John Neff would see a clear operational edge over the competitor.
35.83%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
35.83%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
36.40%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
37.84%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
37.84%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.81%
Share count expansion well above AXSM's 1.48%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.81%
Diluted share count expanding well above AXSM's 1.48%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-14.43%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-14.57%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1885.22%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.95%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
81.42%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-991.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
94.68%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
84.15%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1611.09%
10Y equity/share CAGR above 1.5x AXSM's 247.94%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-55.02%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
127.30%
Positive short-term equity growth while AXSM is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Negative asset growth while AXSM invests at 126.17%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.96%
We have a declining book value while AXSM shows 103.54%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-36.45%
We’re deleveraging while AXSM stands at 1.15%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-19.33%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-34.65%
We cut SG&A while AXSM invests at 36.53%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.